Logo image of ANAB

ANAPTYSBIO INC (ANAB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ANAB - US0327241065 - Common Stock

46.31 USD
-3.95 (-7.86%)
Last: 1/15/2026, 5:27:22 PM
46.31 USD
0 (0%)
After Hours: 1/15/2026, 5:27:22 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ANAB. ANAB was compared to 528 industry peers in the Biotechnology industry. ANAB may be in some trouble as it scores bad on both profitability and health. ANAB is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ANAB has reported negative net income.
  • In the past year ANAB has reported a negative cash flow from operations.
  • In the past 5 years ANAB always reported negative net income.
  • In the past 5 years ANAB always reported negative operating cash flow.
ANAB Yearly Net Income VS EBIT VS OCF VS FCFANAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • With a decent Return On Assets value of -23.97%, ANAB is doing good in the industry, outperforming 72.73% of the companies in the same industry.
Industry RankSector Rank
ROA -23.97%
ROE N/A
ROIC N/A
ROA(3y)-29.09%
ROA(5y)-20.21%
ROE(3y)-146.58%
ROE(5y)-92.2%
ROIC(3y)N/A
ROIC(5y)N/A
ANAB Yearly ROA, ROE, ROICANAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • ANAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANAB Yearly Profit, Operating, Gross MarginsANAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

  • ANAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ANAB has been increased compared to 1 year ago.
  • The number of shares outstanding for ANAB has been increased compared to 5 years ago.
  • The debt/assets ratio for ANAB is higher compared to a year ago.
ANAB Yearly Shares OutstandingANAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ANAB Yearly Total Debt VS Total AssetsANAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 0.13, we must say that ANAB is in the distress zone and has some risk of bankruptcy.
  • ANAB has a better Altman-Z score (0.13) than 60.61% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.13
ROIC/WACCN/A
WACC9.6%
ANAB Yearly LT Debt VS Equity VS FCFANAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • ANAB has a Current Ratio of 8.68. This indicates that ANAB is financially healthy and has no problem in meeting its short term obligations.
  • ANAB's Current ratio of 8.68 is fine compared to the rest of the industry. ANAB outperforms 77.08% of its industry peers.
  • ANAB has a Quick Ratio of 8.68. This indicates that ANAB is financially healthy and has no problem in meeting its short term obligations.
  • ANAB has a better Quick ratio (8.68) than 77.08% of its industry peers.
Industry RankSector Rank
Current Ratio 8.68
Quick Ratio 8.68
ANAB Yearly Current Assets VS Current LiabilitesANAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

  • ANAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.62%, which is quite impressive.
  • Looking at the last year, ANAB shows a very strong growth in Revenue. The Revenue has grown by 196.42%.
  • Measured over the past years, ANAB shows a very strong growth in Revenue. The Revenue has been growing by 62.73% on average per year.
EPS 1Y (TTM)53.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%145.61%
Revenue 1Y (TTM)196.42%
Revenue growth 3Y13.05%
Revenue growth 5Y62.73%
Sales Q2Q%154.26%

3.2 Future

  • ANAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.53% yearly.
  • The Revenue is expected to grow by 42.41% on average over the next years. This is a very strong growth
EPS Next Y75.7%
EPS Next 2Y5.99%
EPS Next 3Y0.94%
EPS Next 5Y10.53%
Revenue Next Year280.61%
Revenue Next 2Y55.39%
Revenue Next 3Y50.06%
Revenue Next 5Y42.41%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ANAB Yearly Revenue VS EstimatesANAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ANAB Yearly EPS VS EstimatesANAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ANAB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANAB Price Earnings VS Forward Price EarningsANAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANAB Per share dataANAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.99%
EPS Next 3Y0.94%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ANAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ANAPTYSBIO INC

NASDAQ:ANAB (1/15/2026, 5:27:22 PM)

After market: 46.31 0 (0%)

46.31

-3.95 (-7.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-25
Inst Owners114.62%
Inst Owner Change-2.6%
Ins Owners2.52%
Ins Owner Change0.93%
Market Cap1.28B
Revenue(TTM)169.47M
Net Income(TTM)-84.63M
Analysts84.21
Price Target58.14 (25.55%)
Short Float %21.65%
Short Ratio10.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)74.85%
Min EPS beat(2)14.78%
Max EPS beat(2)134.93%
EPS beat(4)3
Avg EPS beat(4)51.5%
Min EPS beat(4)-0.12%
Max EPS beat(4)134.93%
EPS beat(8)5
Avg EPS beat(8)21.07%
EPS beat(12)8
Avg EPS beat(12)13.49%
EPS beat(16)8
Avg EPS beat(16)-5.04%
Revenue beat(2)2
Avg Revenue beat(2)231.08%
Min Revenue beat(2)88.94%
Max Revenue beat(2)373.21%
Revenue beat(4)4
Avg Revenue beat(4)246.14%
Min Revenue beat(4)78.26%
Max Revenue beat(4)444.15%
Revenue beat(8)7
Avg Revenue beat(8)203.82%
Revenue beat(12)9
Avg Revenue beat(12)133.49%
Revenue beat(16)9
Avg Revenue beat(16)78.7%
PT rev (1m)-5.39%
PT rev (3m)22.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)196.87%
EPS NY rev (1m)18.59%
EPS NY rev (3m)73.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)175.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)110.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.57
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.82
EYN/A
EPS(NY)-4.57
Fwd EYN/A
FCF(TTM)-5.25
FCFYN/A
OCF(TTM)-5.24
OCFYN/A
SpS6.12
BVpS-1.06
TBVpS-1.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.09%
ROA(5y)-20.21%
ROE(3y)-146.58%
ROE(5y)-92.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.91%
Cap/Sales 0.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.68
Quick Ratio 8.68
Altman-Z 0.13
F-Score4
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)78.6%
Cap/Depr(5y)111.71%
Cap/Sales(3y)2.86%
Cap/Sales(5y)2.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%145.61%
EPS Next Y75.7%
EPS Next 2Y5.99%
EPS Next 3Y0.94%
EPS Next 5Y10.53%
Revenue 1Y (TTM)196.42%
Revenue growth 3Y13.05%
Revenue growth 5Y62.73%
Sales Q2Q%154.26%
Revenue Next Year280.61%
Revenue Next 2Y55.39%
Revenue Next 3Y50.06%
Revenue Next 5Y42.41%
EBIT growth 1Y79.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.74%
EBIT Next 3Y19.67%
EBIT Next 5YN/A
FCF growth 1Y-48.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.26%
OCF growth 3YN/A
OCF growth 5YN/A

ANAPTYSBIO INC / ANAB FAQ

What is the fundamental rating for ANAB stock?

ChartMill assigns a fundamental rating of 3 / 10 to ANAB.


Can you provide the valuation status for ANAPTYSBIO INC?

ChartMill assigns a valuation rating of 0 / 10 to ANAPTYSBIO INC (ANAB). This can be considered as Overvalued.


What is the profitability of ANAB stock?

ANAPTYSBIO INC (ANAB) has a profitability rating of 1 / 10.


How financially healthy is ANAPTYSBIO INC?

The financial health rating of ANAPTYSBIO INC (ANAB) is 3 / 10.